A review of the effects of tibolone on the skeleton

  title={A review of the effects of tibolone on the skeleton},
  author={J. Devogelaer},
  journal={Expert Opinion on Pharmacotherapy},
  pages={941 - 949}
  • J. Devogelaer
  • Published 2004
  • Medicine
  • Expert Opinion on Pharmacotherapy
Osteoporosis is a frequent condition, which can lead to significant morbidity and even to increased mortality, owing to its complications (i.e., the fractures). Several therapies, mostly antiresorbing agents such as oestrogens, antioestrogens (chiefly raloxifene), calcitonin and bisphosphonates, are recognised for the treatment of the condition. More recently, parathyroid hormone has been added to the armamentarium of therapeutic agents. However, except for oestrogens, no other therapy… Expand
Effects of tibolone on the breast of postmenopausal women.
It is concluded that tibolone, if not superior to conventional HT, may be more acceptable to clinicians as a therapeutic drug option for use with symptomatic menopausal women. Expand
Tibolone can improve the climacteric symptoms of perimenopausal women living in Taiwan with the exception of increased body weight, and no major side-effect was noted during this short-term study. Expand
Bone health-related factors and the use of bisphosphonates in community setting—15-year follow-up study
Bone health related factors that were associated with the use of bisphosphonates (BP) among 2,050 postmenopausal Finnish women reveal the recent bone health-related indications for BP prescription. Expand
Sex hormones and related compounds, including hormonal contraceptives
This chapter discusses sex hormones and related compounds including hormonal contraceptives, and Diethylstilbestrol has clearly been shown to cause primary vaginal carcinoma in the second generation and tumors continue to occur in women in middle age. Expand
Growth factor delivery for bone tissue repair: an update
This review provides a selective summary of recent attempts for GF delivery in bone tissue regeneration and an alternative means of GF delivery, namely the delivery of genes coding for osteogenic proteins, rather than the Delivery of the proteins, is summarised from rodent models. Expand
La tibolone face aux exigences de la médecine factuelle
Ces métabolites et une très faible quantité résiduelle de tibolone sont distribués par voie sanguine aux différents organes cibles, principalement sous une forme sulfatée inactive. Expand
Enantioselective production of 3-hydroxy metabolites of tibolone by yeast reduction
A restricted screening performed among 52 yeasts showed that the 3alpha-epimer was preferentially obtained with high epimeric purity with various strains (i.e. with Kluyveromyces lactis lactis CBS 2359), while only Saccharomyces cerevisiae CBS 3093 gave the 3beta-EPimer as major product. Expand


Use of pamidronate in chronic and acute bone loss conditions.
In children with OI, oral APD therapy has produced a dramatic increase in bone mass, without adversely interfering with the growth spur, and Intravenous APD administered daily for twelve days has provoked a dramatic improvement in patients with long lasting RSDS which had resisted to various well-accepted therapies. Expand
Tibolone: a review.
Tibolone appears to be at least as efficacious as other forms of hormonal replacement therapy (HRT) on climacteric symptoms and seems to exert a similar effect as other form of HRT on markers of bone metabolism and bone mass, but no data is yet available on fracture prevention. Expand
Effect of tibolone on postmenopausal bone loss
It is found that tibolone given in the early postmenopausal years suppresses skeletal metabolism and prevents bone loss in both spine and femur, and has a potentially important long-term role in the reduction of the incidence of osteoporotic fractures. Expand
Effects of 8 Years of Treatment with Tibolone 2.5 mg Daily on Postmenopausal Bone Loss
It is concluded that tibolone 2.5 mg daily prevents bone loss in the lumbar spine and femoral neck over 8 years and adherence to treatment is high and the greater bone density compared with untreated women would be expected to reduce the risk of bone fractures. Expand
Tibolone: a steroid with a tissue-specific mode of action
  • H. Kloosterboer
  • Medicine, Biology
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2001
It is concluded that tibolone acts as a tissue-specific compound by mediating its effects via steroid receptors and enzymatic pathways, and avoids stimulation of the endometrium and breast tissue. Expand
Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
The combined regimen of androgens and ERT increased vertebral bone mass and enhance sexual activity in postmenopausal women equal to that of tibolone and to a greater extent than ERT alone; its effects on lipids, however, are clearly adverse. Expand
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.
The effects of treatments on the risk of vertebral and nonvertebral fractures and on bone density, including effects in different patient subgroups are summarized and an estimate of the expected impact of antiosteoporosis interventions in prevention and treatment populations is provided using the number needed to treat (NNT) as a reference. Expand
Tibolone: prevention of bone loss in late postmenopausal women.
Within 2 yr of treatment, tibolone increases bone mass in the spine and prevents bone loss in the forearm in late postmenopausal women determined by densitometry and several biochemical parameters of bone turnover. Expand
Prevention of post-oophorectomy bone loss with tibolone
It is concluded that Tibolone is effective in the prevention of the post-ovariectomy accelerated bone loss and in retaining the initial premenopausal bone mass, at least during the first post-oophorectomy year. Expand
Prevention of post-oophorectomy bone loss with tibolone
It is concluded that Tibolone is effective in the prevention of the post-ovariectomy accelerated bone loss and in retaining the initial premenopausal bone mass, at least during the first post-oophorectomy year. Expand